“Efficacy and Safety of up to Two Years of Tralokinumab Treatment in Adults of Different Racial Subgroups With Moderate-to-Severe Atopic Dermatitis”. 2023. SKIN The Journal of Cutaneous Medicine 7 (2): s144. https://doi.org/10.25251/skin.7.supp.144.